MetLife Investment Management LLC Sells 1,550 Shares of Illumina, Inc. (NASDAQ:ILMN)

MetLife Investment Management LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 82,335 shares of the life sciences company’s stock after selling 1,550 shares during the period. MetLife Investment Management LLC owned approximately 0.05% of Illumina worth $10,737,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Versant Capital Management Inc lifted its position in Illumina by 292.9% in the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 246 shares in the last quarter. Industrial Alliance Investment Management Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at about $34,000. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after purchasing an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in shares of Illumina during the second quarter worth about $61,000. Finally, Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ILMN. UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. StockNews.com began coverage on shares of Illumina in a research report on Thursday, August 29th. They set a “buy” rating on the stock. Daiwa America upgraded Illumina to a “strong-buy” rating in a report on Friday, August 16th. Finally, Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $164.00.

Illumina Trading Up 1.0 %

Shares of Illumina stock opened at $144.36 on Friday. Illumina, Inc. has a 52-week low of $93.51 and a 52-week high of $156.66. The stock has a market cap of $22.90 billion, a PE ratio of -14.49 and a beta of 1.13. The firm has a 50-day moving average of $141.62 and a 200-day moving average of $125.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the business posted $0.33 EPS. The business’s revenue was down 3.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Illumina, Inc. will post 4.11 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.